# rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

> **NCT04035733** · PHASE2 · COMPLETED · sponsor: **AKARI Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Bullous Pemphigoid (BP)

## Interventions

- **DRUG:** rVA576

## Key facts

- **NCT ID:** NCT04035733
- **Lead sponsor:** AKARI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-04-29
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04035733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04035733, "rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04035733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*